tradmap

AMIX Financials Autonomix Medical, Inc.

4 years of revenue, profit, cash flow and balance-sheet history through FY2026, from SEC filings — with a computed, factual read of the trend. Updated Overview →

Financial health

  • The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
Revenue & net income
-$17M -$8M $0 2023 2024 2025 2026
RevenueNet income
Margins (gross / operating / net)
0% 50% 100% 2023 2024 2025 2026
GrossOperatingNet
Free cash flow (CFO − capex)
-$12M -$6M $0 2023 2024 2025 2026
Free cash flow
Cash vs total debt
$0 $5M $9M 2023 2024 2025 2026
CashTotal debt
Cash flow: operating / investing / financing
-$12M $1M $14M $0 2023 2024 2025 2026
OperatingInvestingFinancing

Key annual figures

FYRevenueNet incomeGross MOp MFCFTotal debtCash
2026 $0 -$17M -$12M $7M
2025 $0 -$11M -$8M $9M
2024 $0 -$15M -$7M $9M
2023 $0 -$2M -$2M $0 $865000

Frequently asked questions

Is AMIX growing its revenue and profit?

See the revenue and net-income charts above for Autonomix Medical, Inc.'s multi-year trend.

How much debt does AMIX have?

As of FY2026, Autonomix Medical, Inc. reported — of total debt against $7M of cash.

What is AMIX's profit margin?

In FY2026, gross margin was —, operating margin —, and net margin —.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.